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A. 1. INTRODUCTION 
 
Highly active antiretroviral therapy (HAART) has dramatically affected the course of HIV disease, 
resulting in a significant reduction in AIDS-related morbidity and mortality in both developed1 and 
developing2 countries.  
 
Adherence to antiretroviral therapy is the single most important determinant of clinical outcomes3 4 
and a dose-response relationship has been demonstrated for virological suppression and adherence. 
5 One study of HIV treatment naïve patients found that 95% adherence was associated with 
maximal therapeutic effects of antiretroviral therapy. The optimal level of adherence may vary 
according to the drugs being administered, but strategies to improve adherence remain critical to 
successful outcomes on any HAART regimen.6 
 
HAART is life-long and often comprises complicated dosing schedules of medicines that induce 
numerous side-effects, and for this reason HAART h s been described as the most rigorous oral 
medication regimens ever offered.7 A range of barriers to adherence have been reported in the 
literature, including: fear of disclosure, side-effects, concomitant substance abuse, forgetfulness, 
suspicions of treatment, regimens that are too complicated, decreased quality of life, competing 
work and family responsibilities, and challenges to consistent access to medication.8   
Numerous behavioral interventions have been developed to support adherence, including 
adherence case management, counseling, pharmacist-based education, telephone support, reminder 
devices, nurse home visits, and directly observed therapy.9 10 11 Among these, direct observation is 
perhaps the most contentious.12  
 
Directly observed therapy (DOT) involves a health care worker or other designee watching the 
patient swallow their medicines. DOT was developed as an adherence support strategy for 
tuberculosis programmes in the 1960s,13 and has been promoted by the World Health Organization 
from the early 1990s as part of its global TB control strategy.14 However, concerns have been raised 
with respect to the poor evidence of effectiveness and the high cost of this approach.15 A 
systematic review of 11 randomized and quasi-randomized trials found no benefits of DOTS over 
self-administration of treatment.16 
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TB and HIV treatment differ in a number of ways. The most important difference is that TB 
treatment is of limited duration (6-8 months for non-resistant strains) whereas HAART is a life-
long treatment. Concerns raised regarding the feasibility and cost-effectiveness of DOT for TB15 
are therefore even more relevant for HAART.  Nevertheless, DOT has been promoted as a viable 
adherence support strategy for HAART in less-developed countries. 
 
A number of observational studies17 18 19  and randomized trials of DOT HAART20 21 have been 
conducted in recent years, with mixed results. One trial conducted in Cape Town, South Africa, 
was recently terminated due to futility.22  
 
Given the conflicting evidence from individual trials, this study proposes a systematic review and 
meta-analysis of the current evidence.  A systematic review is an overview of primary studies that is 
conducted according to explicit and reproducible methodology. The use of an explicit methodology 
to identify studies according to a pre-defined criteria aims to limit bias and provide a reliable and 
accurate synthesis of the current evidence.  A meta-analysis is a statistical technique for synthesizing 
of the results all studies to provide a single (pooled) estimate of effect.23 No systematic reviews of 
DOT HAART trials have been published to date. 
 
A.1.1 Objective 
 
The objective of this study is to undertake a systematic review of all randomized and quasi-
randomized trails of DOT versus non-DOT HAART among adults to assess whether the former 
leads to greater adherence and improves clinical outcomes for HIV/AIDS patients compared to 
the latter. 
 
 A.2. METHODS 
 
A.2.1. Inclusion criteria  
 
A.2.1.1 Types  o f  s tudies  
 
Randomized and quasi-randomized trials.∗  
 
                                                   
∗ A trial using a quasi-random method of allocating participants (such as alternation) 
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A.2.1.2 Types  o f  pa rt i c i pan ts  
 
Adults on HAART. HAART is defined as at least three antiretroviral drugs consisting of: at least 
one protease inhibitor; at least one non-nucleoside reverse transcriptase inhibitor; or three or more 
nucleoside reverse transcriptase inhibitors, of which one is abacavir. This definition is in keeping 
with a recent Cochrane review of adherence interventions to HAART.24 
 
A.2.1.3 Types  o f  int er ven t ion s 
 
Intervention: Direct observation of administration of HAART. This may be either full (all pills) or 
modified (a proportion of pills) 
Control: non directly-observed administration of HAART. 
 
A.2.1.4 Types  o f  o utcomes 
 
This review will have to consider the following primary and secondary endpoints:  
  
Primary 
• viral load, expressed as the number of patients achieving virological suppression. 
 
Secondary 
• any measure of adherence to HAART. Where more than 1 adherence measurement is 
used, data on all measures will be extracted and the most objective method chosen for 
analysis (e.g. electronic monitoring)8 
• immunological progression (as measured by CD4 cells/mm3) 
• all cause mortality  
• development of new resistance mutations 
• new or recurrent AIDS-defining illnesses 
 
A.2.2. Search strategy for identification of studies 
 
The proposed review will attempt to identify all relevant studies regardless of language or 
publication status (published, unpublished, in press and in progress).  Trial registers and databases 
will be searched for all studies using a highly-sensitive search strategy developed for this study (see 
Annex A.1).   
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For databases that do not allow the use of highly-sensitive search strategies, a simple search strategy 
will be used as follows: (Direct observation OR Directly observed OR DOT OR DAART) AND 
(ART OR HAART OR Antiretroviral). 
 
A.2.2.1.  Databases  to  b e  se ar ched 
 
The following electronic databases will be searched using the highly sensitive search strategy: 
• MEDLINE 
• EMBASE 
• Cochrane CENTRAL 
• CINAHL 
• PsycInfo 
 
Databases to be searched according the simple search strategy include: 
 
Database of publications: 
• LILACS (La Literatura Latinoamericana y del Caribe de Informacion en Ciencias de Salud) 
www.bireme.br 
Clinical trials registers: 
• US National Institutes of Health: www.clinicaltrials.gov 
• Current Controlled Trials: www.controlled-trials.com 
Abstract databases of major HIV/AIDS conferences: 
• Conference on retroviruses and opportunistic infections (1998-2009): 
www.retroconference.org   
• International AIDS Society Conferences (2001-2009): 
http://www.iasociety.org/AbstractSearch.aspx?search=Search%20IAS%20Abstract%20Ar
chive  
• International Conference on HIV Treatment Adherence (www.iapac.org) 
Grey literature sites:  
• Google Scholar: www.scholar.google.com 
• The networked digital library of theses and dissertations: www.ndltd.org 
• AIDS Treatment News: http://www.aidsnews.org/ 
• The Body http://www.thebody.com/ 
• Canadian AIDS Treatment Information Exchange publications: http://www.catie.ca/ 
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The bibliography of review articles and primary studies will also be scanned, and experts in the field 
of HAART adherence will be contacted to identify additional trials (unpublished and ongoing).  
 
A.2.3. Study selection 
 
The results of the search will be screened to select potentially relevant studies. Two or more 
reviewers will independently apply eligibility criteria based on the study design, types of 
participants, and intervention detailed above. Differences in opinion will be resolved through 
discussion with a third party. Where the abstracts are unclear or there is any other reason for 
uncertainty, the full article will be obtained before making any decision regarding eligibility for 
inclusion. When abstracts are not available in English the assistance of translators will be sought.  
 
A.2.4. Data extraction 
 
Data extraction will be done according to the data extraction forms presented in Annex A.2. with 
all data independently cross-checked and disagreements resolved by a third party. The following 
information will be extracted for each trial: 
 
Tr ial  c haract er is t i c s   
• Method of randomization 
• Allocation concealment 
• Blinding 
• Type, frequency and duration of follow up 
• Duration of trial 
• Adherence assessment 
Par t i c i pant cha rac ter is t i c s  
• Number (sample size) 
• Gender 
• Age  
Inte r ven t ion  c ha ra cte ris t i c s  
• Intervention 
- Drug regimen 
- Type and frequency of DOT 
- Location 
- Observer 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 11 
• Control 
- Drug regimen 
- Administration 
- Location 
Outcome s 
• Primary outcomes 
• Secondary outcomes 
 
A.2.5. Assessment of methodological quality of trials 
 
The quality of included trials will be independently assessed by two investigators using a checklist to 
rate the following issues (Annex A.3.): 
• Methods of randomization 
• Concealment of allocation 
• Blinding status (of analyst) 
• Analysis done as intention-to-treat 
• Loss to follow up of greater than 20% 
 
Differences in opinion will be resolved through discussion with a third party. 
 
A.2.6. Data Analysis 
 
Estimates of effect will be pooled using relative risks for binary data. Heterogeneity will be assessed 
by forest plot and calculation of the I2 statistic. In the absence of homogeneity of effects, a random 
effects model will be used. Primary and secondary outcomes will be included in the meta-analysis. 
Sensitivity analyses will be done using a univariate random-effects logistic regression model to 
assess the following: high- vs low-risk groups, type of DOT, trial location, trial duration, prior 
treatment experience and allocation concealment. 
 
A.3. ETHICS 
 
Systematic reviews draw on publicly available data and do not directly involve human subjects, and 
therefore do not require formal ethical review. Nevertheless some ethical principles for clinical 
research can be extended to systematic reviews, notably the principles of scientific validity and 
independent review.25 These are noted below. 
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Scientific validity requires, among other things, that the scientific design of the research realizes 
social value, which implies that a dissemination strategy be planned in advance of the study. The 
results of this review will be disseminated through submission of an article to a peer-review journal. 
In addition, copies of the article will be sent to all investigators involved in DOT HAART studies 
contacted during the course of this study. 
 
Independent review requires that public accountability is met through scientific review according to 
international standards. This study protocol will be reviewed by experts with knowledge of both 
methodology (systematic reviews and meta-analyses) and content (HAART adherence) and 
submitted to the University of Cape Town Departmental Research Committee for approval. 
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ANNEX A.1 
 
HIGHLY-SENSITIVE SEARCH STRATEGY∗ 
 
1 human immunodeficiency virus 
2 human immunodeficiency virus infection 
3 anti human immunodeficiency virus agent 
4 hiv.tw.  
5 human immunodeficiency.tw.  
6 acquired immunodeficiency syndrome.tw.  
7 acquired immune deficiency syndrome.tw.  
8 aids.tw. 
9 or/1-8 
10. patient compliance 
11. complian:.tw.  
12. comply.tw.  
13. complied.tw.  
14. noncomplian:.tw. 
15. non-complian:.tw.  
16. adher:.tw.  
17. non-adher:.tw.  
18. nonadher:.tw.  
19. or/10-18  
20. direct observation 
21. directly observed 
22. direct observ:.tw. 
23. directly observ:.tw. 
24. DOT 
25. DAART 
26. supervis:.tw. 
27. or/20-26 
28. randomization 
29. random:.tw.  
30. double blind procedure 
31. single blind procedure 
32. clinical trial 
33. meta analysis  
34. meta-analy:.tw.  
35. or/28-34 
36. 9 and 19 and 27 and 35 
 
 
 
                                                   
∗ Adapted from highly sensitive search strategies used in Cochrane reviews of treatment adherence 
in TB16 and HIV24 
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 ANNEX A2: DATA EXTRACTION FORM 
 
 
First author: 
 
Full article title:  
Notes:  
_____________________________________________________________________________ 
_____________________________________________________________________________ 
 
TRIAL CHARACTERISTICS 
 
Randomization method:  
Allocation concealment:  
Duration of trial:  
Duration of follow up:  
 
Loss to follow up 
 Intervention Control Total 
Total number randomized    
Number available at follow up    
Number Loss to follow up    
Number Died    
Other    
 
Was analysis done as intention to treat  Yes   No        Unclear  
 
Adherence assessment 
 Yes No Unclear 
Viral Load    
Electronic monitoring  
Indicate type (eg MEMS) 
   
Patient self-reports 
Indicate type (medication diaries) 
   
Provider Reports 
Indicate type (pill count) 
   
Clinical progression    
Clinic/pharmacy records    
Other 
Specify 
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PARTICIPANT CHARACTERISTICS 
 
Country and setting: 
______________________________________________________________ 
 
Number of persons in trial 
 Intervention Control Total 
Number    
% of Total   100% 
 
Gender  
 Intervention Control Total 
 N % N % N % 
Male       
Female       
Total       
 
Age  
 Intervention Control Total 
Mean Age    
 
 
INTERVENTION CHARACTERISTICS 
 
Intervention (DOT) 
Drug regimen(s)  
Frequency 
Once a day 
Twice a day 
 
Administration 
Health care provider 
Family member, peer supporter 
Other 
 
Location 
Health centre 
Home 
Other 
 
Other remarks  
 
Control (non-DOT) 
Drug regimen(s)  
Administration 
Self-administration 
Other 
 
Location 
Health centre 
Home 
Other 
 
Other remarks  
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OUTCOMES 
 
1. Primary outcomes: Viral load 
 
 
 Intervention 
N (%) 
Control 
N (%) 
Number with viral load 
undetectable 
  
 
 
2. Secondary outcomes 
 
a) Adherence (describe according to measure used): 
 
 
 
b) Other events 
 Intervention 
N (%) 
Control 
N (%) 
Mortality (any cause)   
Immunological progression   
Development of new resistance 
mutations 
  
Any HIV-associated events   
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ANNEX A3: ASSESSMENT OF METHODOLOGICAL QUALITY1 
 
Reviewers Initials:  
 
Validity criteria        
 
1. Formation of groups 
 Random allocation      
 Quasi-random allocation      
 Selected controls      
 Not stated       
2. Experimental confounders 
Baseline difference between groups potentially related to outcome 
 No, or yes but statistically adjusted    
 Yes, no statistical adjustment     
 Can’t tell       
3. Unit of allocation 
 patient        
 group        
 clinic        
4. Concealment of allocation 
 random        
 quasi-random       
 not stated         
5. Blinding 
 Assessor blinded      
 no blinding or not stated      
6. Outcome measures 
 Objective (not open to interpretation) or 
 Subjective (raters blind to allocation)    
 Subjective with no blinding but with 
explicit criteria for outcome definition    
 Subjective with no blinding but with 
no mention of explicit criteria     
7. Intention to treat analysis 
 Yes        
 No        
8. Follow up 
 Outcome reported for >90% of participants   
 Outcome reported for 80-90% of participants   
 Outcome reported for <80% of participants   
                                                   
1 Adapted from Haynes B. Conducting Systematic Reviews In: Haynes R, Sackett D, Guyatt G, 
Tugwell P. Clinical Epidemiology: How to do clinical practice research (third edition). Lippincott 
Williams & Wilkins, Baltimore, 2006.26 
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B.1. Abstract 
Background: Directly observed therapy of highly active antiretroviral therapy (DOT-HAART) 
has been suggested for both high-risk populations for improving poor adherence and 
generalized epidemics.  
Objectives: We conducted a systematic review and meta-analysis of randomized trials of DOT 
HAART versus self-administered treatment. 
Data sources: Using a highly sensitive search strategy, duplicate searches were conducted for 
the following databases from inception to March 26, 2009: MEDLINE via PubMed, 
EMBASE, Cochrane CENTRAL, CINAHL, PsycInfo, LILACS, Current Controlled Trials and 
US National Institutes of Health. Searchable websites of major HIV conferences (IAS, IAPAC 
and CROI) and grey literature websites complemented this search. Investigators of all 
identified unpublished trials were contacted. 
Review methods: Abstracts were scanned in duplicate for all randomized and quasi-
randomized trials comparing direct observation of HAART administration with non directly-
observed administration of HAART among adults. Our primary outcome was virological 
suppression at study completion. Secondary outcomes included self-reported adherence, 
immunological changes (CD4 T-cell), loss-to-follow up, all cause mortality, resistance 
mutations, and major AIDS-defining events.  We calculated relative risks (RR) and appropriate 
95% Confidence Intervals (CIs) for all primary and secondary outcomes. Pooled estimates 
were calculated using a random effects method. Sensitivity analyses assessed high and low risk 
groups, study duration and location, and allocation concealment. We applied a Bayesian 
sensitivity analysis on our primary outcome and conducted a post-hoc optimal information size 
to determine whether effect sizes were adequate to conclusively determine an effect. 
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Results: Twelve studies met our inclusion criteria, of which four were done in groups 
considered at high risk of poor adherence (drug users and homeless). Of the 10 studies 
reporting our primary outcome (n=1862) we found a pooled non-significant effect of RR 1.04 
(95% CI, 0.91-1.20, P=0.55, I2= 53.8%, 95% CI, 0-76%, P=0.02) for viral suppression at study 
completion. Bayesian results were no different (RR 1.05, 95% credible intervals 0.96-1.14). 
Self-reported adherence (RR 1.02, 95% CI, 0.98-1.06, P=0.26), immunological progression 
(CD4 T-cell change 0.35, 95% CI, -2.49 – 3.20, P=0.80, 0% 96%CI 0-56%, P=0.71) and all-
cause mortality (95% CI, 0.41-1.07, P=0.09) were all non-significant. Our optimal information 
size indicates a further 17,000 patients with a similar baseline risk need to be randomized to 
detect conclusively any potential effect of DOT-HAART.  
Conclusion: DOT offers no benefit over self-administration of antiretroviral therapy.  
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B.2. Introduction 
Highly active antiretroviral therapy (HAART) has dramatically affected the course of HIV 
disease, resulting in an important reduction in AIDS-related morbidity and mortality in both 
developed and developing countries. 1,2  
 
Strategies to improve adherence remain critical to successful outcomes on any HAART 
regimen.3 HAART is life-long and requires high levels of adherence to ensure maximum 
virologic outcomes,4,5 prevent antiretroviral drug resistance,6,7 prevent disease progression,8 and 
improve survival.9 Numerous behavioral interventions have been developed to support 
adherence including adherence case management, counseling, pharmacist-based education, 
telephone support, reminder devices, nurse home visits, and directly observed therapy 
(DOT).10,11,12 Among these, direct observation is perhaps the most contentious.13,14  
 
Directly observed therapy involves a health care worker or other designee witnessing the 
patient swallow their medicines. DOT was developed as an adherence support strategy for 
tuberculosis (TB) programmes in the 1960s,15 and has been promoted by the World Health 
Organization since 1994 as part of its global tuberculosis (TB) control strategy. However, 
concerns have been raised with respect to the poor evidence of effectiveness and the high cost 
of this approach.16 A systematic review of TB randomized trials found no benefits of DOT 
over self-administration of treatment.17 Critics have also raised concern that DOT is coercive 
to patient autonomy.18,19 
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TB and HIV treatment differ in a number of ways. The most important difference for patients 
is that TB treatment is of limited duration (6-8 months for non-resistant strains) whereas 
HAART is a life-long treatment. Concerns raised regarding the feasibility and cost-
effectiveness of DOT for TB are therefore even more relevant for HAART.  Nevertheless, 
DOT has been promoted as a potential adherence support strategy for HAART, largely on the 
basis of small observational studies.20,21  
 
Given the potential cost to both patients and health services of implementing DOT 
programmes for HAART there is a need for clear evidence of its benefit as an adherence 
support strategy. We conducted a systematic review and meta-analysis of randomized trials of 
DOT HAART versus self-administered treatment. 
 
B.3. Methods 
B.3.1. Elig i bi l i t y  c r i t e r ia 
We included all randomized trials assessing direct observation of antiretroviral therapy as an 
intervention to promote adherence as a primary or secondary outcome within any adult 
population in any setting. We considered the supervised swallowing of HAART pills as direct 
observation. We included randomized clinical trials (RCTs) of any duration or exposure to 
DOT, regardless of regularity and examined differences in a sensitivity analysis. We included 
studies among adult populations receiving any antiretroviral combination therapy in any dosing 
format. Non-randomized studies were excluded. 
 
B.3.2. Se arc h s t rat egy  
We developed a highly sensitive search strategy (Search strategy provided in Appendix) 
combining key terms that may indicate adherence (e.g. adherence, compliance, directly 
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observed, DOT) with the MeSH headings “HIV” or “Acquired Immunodeficiency Syndrome” 
and search terms for randomized trials from January to April 2009. Initial searches were 
developed (NF, JN). Investigators then searched independently (NF, EM), in duplicate the 
following databases (from inception to March 26, 2009): MEDLINE via PubMed, EMBASE, 
Cochrane CENTRAL, CINAHL, PsycInfo, LILACS, Current Controlled Trials 
(www.controlled-trials.com) and US National Institutes of Health (www.clinicaltrials.gov),  and 
the searchable websites of major HIV conferences: all International AIDS Society conferences 
(up to Mexico, August 2008) and all  Conferences on Retroviruses and Opportunitistic 
Infections (up to Montreal, February 2009). We also hand searched abstracts of the 
International Conference on HIV Treatment Adherence (International Association of 
Physicians in AIDS Care, Miami, April 2009) and searched a number of lay publications and 
websites, including The Body, the Canadian AIDS Treatment Information Exchange 
publications, AIDS Treatment News, Google Scholar and the networked digital library of 
theses and dissertations (ww.ndltd.org). Our search was complemented by reviewing 
bibliographies of relevant papers and contacting individual clinical researchers and AIDS trials 
groups through email and phone (National Institutes of Mental Health, International AIDS 
Society, and International Association of Physicians in AIDS Care); from our searches, we had 
identified all studies matching our inclusion criteria suggested by these groups. We contacted 
all potentially relevant study authors by email and telephone for details on their trials. One of 
the authors (JN) was primary investigator on a trial. 
 
B.3.3. Study  s e le c t i on 
Using a predefined protocol (available from the corresponding author on request), two 
investigators (NF, EM) worked independently, in duplicate, scanning all abstracts and 
obtaining the full text of articles and abstracts that indicated or suggested that direct 
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observation of pill-taking was conducted. After obtaining full reports of the candidate studies 
(either in full peer-reviewed publication, conference abstract or non peer-reviewed article)  the 
same reviewers independently assessed eligibility.  Reviewers were not blinded to study authors, 
study conclusions and outcomes as blinding has been shown to have little effect on systematic 
reviews.22 To obtain full information regarding conference abstracts and registered trials, we 
attempted contact with all study authors for full information through email and telephone 
communication. After all potentially relevant full-text articles and abstracts were identified, we 
consulted as a team (NF, JN, EM) to achieve consensus regarding eligibility and consulted an 
arbitrator (ME) for adjudication. 
 
B.3.4. Data extrac t ion  
During March 2009, we conducted data extraction independently and in duplicate, using a 
standardized, pre-piloted form. Data abstractors collected information about the study setting, 
study populations, sample size, and methods of adherence measurement. Because there is no 
gold standard for evaluating adherence to medication,23 we included different measures of 
adherence as reported in the studies. Our primary endpoint was the number of individuals in 
the exposure and control groups achieving viral suppression at study endpoint.  Secondary 
outcomes include all-cause mortality; immunological progression (as measured by CD4 T-
cells/mm3); development of resistance mutations; and new or recurrent AIDS-defining 
illnesses. We entered the data into an electronic database such that duplicate entries existed for 
each study and when the two entries did not match we reached consensus through discussion. 
We considered study quality according to reporting of randomization method, adjustment of 
experimental confounders, allocation concealment, blinding of analysts, objectivity of outcome 
measures, use of intent-to-treat analysis, and loss to follow-up larger than 20%. 
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B.3.5 . Data analys i s  
 
In order to assess inter-rater reliability on inclusion of articles, we calculated the Phi statistic, 
which provides a measure of inter-observer agreement independent of chance.24 We calculated 
the Relative Risk (RR) and appropriate 95% Confidence Intervals (CIs) of the primary and 
secondary outcomes according to the number of events reported in the original studies or sub 
studies as intent-to-treat analyses. Where studies did not report intent-to-treat, we analyzed 
outcomes as all-patients randomized.21 In the unlikely event of zero outcome events in one arm 
of a trial, we prepared to apply the Haldane method and add 0.5 to each arm.22 We pooled 
studies as an analysis of all-DOT combined using the DerSimonian-Laird random effects 
method,23 which recognizes and anchors studies as a sample of all potential studies, and 
incorporates an additional between-study component to the estimate of variability.24 We 
calculated the I2 statistic for each analysis as a measure of the proportion of the overall 
variation that is attributable to between-study heterogeneity,25 and calculated the appropriate I2 
confidence intervals.26 We ran a sensitivity analysis on our primary outcome using a Bayesian 
random effects model with Monte Carlo Markov Chain simulations of variability.25 Given the 
expected small number of included trials we conducted univariate sensitivity analysis assessing 
the impact of study quality as determined by groups at high vs low risk for non-adherence, 
prior treatment experience, the impact of study duration defined as short (≤6 months) or long 
term (>6 months) and allocation concealment reporting on outcomes and intervention versus 
post-intervention outcomes. We assessed CD4 T-cell changes by applying a weighted mean 
difference meta-analysis and transformed data to mean and standard deviations (SD) when 
reported as median and ranges.26 We calculated the optimal information size post-hoc for our 
meta-analysis on the primary outcome of viral suppression to determine the conservative 
number of patients required to provide an authoritative answer of therapeutic efficacy.27 We 
imputed the experimental and control event rates from our meta-analysis and applied a 95% 
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power at the 5% significance level. Primary outcomes are reported as intent-to-treat. Forest 
plots are displayed for each all-DOT analysis, showing individual study proportions with 95% 
CIs, and the overall DerSimmonian-Laird pooled estimate. All p-values are exact and 2-sided. 
We considered a p-value <0.05 to be significant. Analyses were conducted using StatsDirect 
(version 2.5.2, www.statsdirect.com), Stata (version 9, www.stata.com), and OpenBUGS 
version 2.1. (www.mathstat.helsinki.fi.libaccess.lib.mcmaster.ca/openbugs/). 
 
B.3.6. Ro le  o f  t he  Fundin g Source  
We did not receive funding for this study. 
  
B.4. Results 
 
From our initial searches up to March 2009, we identified 942 abstracts of full text articles, 
among which 83 studies passed first screening. There was near perfect agreement between 
reviewers on inclusion of abstracts for further analysis (Phi=0.91). A flow diagram of studies 
included in the analysis is detailed in Figure 1. 
 
Table 1 displays the study characteristics. Overall, 12 studies were included for analysis. All full-
text papers and abstracts were published in English. Six studies were conducted within 
USA;28,29,30,31,32,33  another five were conducted in Africa (in Kenya,34 Mozambique,35 Nigeria,36 
and South Africa,37,38), and one was a multi-site study conducted in the USA and South 
Africa.39 Authors provided additional data for five abstracts31,32,33,37,39 and partial data for one 
unpublished, completed study.38 We failed to secure sufficient data for two identified studies 
(authors did not respond).40,41  
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When we examined study reporting of methodological features in full-text studies and where 
authors provided information (n=7), we found moderate reporting of important 
methodological issues. Six studies reported sequence generation,29,30,34,35,37,42 three allocation 
concealment,34,35,37 none reported blinding of study analysts, and four reported results as a full 
intention-to-treat analysis, 28,30,37,42  the others as modified intent-to-treat. Five reported an 
overall proportion lost-to-follow up of less than 20%.28,29,35,37,42 
 
The method of implementing DOT varied across studies. Three studies used directly 
observation of every study dose,29,32,37 the rest had a modified DOT regimen whereby only a 
proportion of doses was observed. Two studies32,34 used health workers as observers; the rest 
used community or peer supporters.  All studies used self-administered pill-taking (SAT) as the 
control intervention.  
 
B.4.1. Meta-analysis 
B.4.1.1.Viral Suppres s ion 
When we pooled all studies as an analysis of all-DOT versus SAT that reported our primary 
outcome of viral suppression (total n=1863), we found a pooled non-significant effect of RR 
1.04 (95% CI, 0.91-1.20) on viral suppression at the study completion. (Figure 2.) Bayesian 
results were no different (RR 1.05, 95% credible intervals 0.96-1.14) When we examined the 
four studies enrolling populations considered at high risk of non-adherence (drug users28,29,33 
and homeless31) we found a relative risk of 1.31 (95% CI, 1.00-1.71, P=0.05); for general 
populations the relative risk was 0.96 (95% CI, 0.82-1.13, P=0.63, I2=58.3%, 95% CI, 0-81.1%, 
P=0.03, test for difference P=0.64). Studies using full observation29,37 (every dose) were not 
significantly different than those using modified DOT (P=0.54). Studies reporting allocation 
concealment34,35 were not different than those that did not report it (0.27). Three studies 
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reported on prior treatment experience28,30,43 but information was insufficient to undertake a 
sensitivity analysis. Duration of study (≤6 months29,30,33,36 vs >6 months) did not significantly 
affect outcome (P=0.82). Studies conducted in Africa34,36,37,38 were not significantly different 
from studies conducted in the USA (P=0.60). No significant heterogeneity was found to be 
present amongst the studies comprising the meta-analyses (P=0.55, I2= 53.8%, 95% CI, 0-
75.5%, P=0.02) (Figure 3.)  
 
We were able to extract data on the following secondary outcomes: self-reported adherence, 
immunological change, loss-to-follow up, all-cause mortality, resistance mutations, and new or 
recurrent AIDS-defining illnesses (Table 2). 
 
B.4.1.2. Se l f -repo rt ed adhe rence  
Self-reported adherence was available for six studies (total n=1,308),30,32,34,35,37,39 defined as any 
pills missed during a limited (<1 week) recall period. We found a pooled RR of 1.02 (95% CI, 
0.98-1.06, P=0.29, I2=0%, 95% CI, 0-61%, P=0.94). Two of the trials reported adherence data 
on only a subset of patients.30,34  
 
B.4.1.3. Immunologi c al Changes  
Eight studies were included in our assessment of CD4 changes between groups at study 
conclusion (total n=1577). We were unable to display a significant weighted mean difference 
between the DOT and SAT arms (CD4 T-cell change 0.35, 95% CI, -2.49 – 3.20, P=0.80). 
 
B.4.1.4. Loss -to - fo l low -up 
When we assessed loss to follow-up among trials, we pooled data from nine trials (n=1,635) 
and found a pooled RR of 1.00 (95% CI, 0.75-1.32, P=0.97). One study reported a high 
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number of refusals to participate in the intervention arm post-randomization28 but this did not 
contribute to identifiable heterogeneity between studies (I2=0%, 95% CI, 0-54.4%, P=0.45).  
 
B.4.1.5. Al l-c ause  mort al i t y  
We assessed the impact of DOT on all-cause mortality from six trials (total n=1,490), and 
found a pooled RR of 0.67 (95% CI, 0.41-1.07, P=0.09, I2=0%, 95% CI, 0-59%, P=0.59) 
indicating that mode of therapy made no important difference on all-cause mortality.  
 
B.4.1.6. Res i s tance  mutat ions  
The development of resistance mutations was only reported for two trials,42,44 with no 
difference between DOT and SAT arms (RR 1.66, 95% CI, 0.47-5.90, P=0.42). 
 
B.4.1.7. New or re cu rre nt  AIDS-de f ini ng i l l ne s s e s  
Three trials reported on AIDS-defining events30,37,39 and had a non-significant difference 
between DOT and SAT arms (RR 0.92, 95% CI, 0.44-1.95, P=0.83; I2 = 49.8% 95% CI, 0-
84.5%, P=0.14).  
 
B.4.1.8. Opt ima l in fo rmat ion s i ze  
We applied a post-hoc sample size calculation, the optimal information size,27,45 whereby the 
median event rates across control and intervention arms were used to determine the 
appropriate sample size required to evaluate a therapeutic role of DOT. Given that this post-
hoc analysis is based on actual data from RCTs rather than expected event rates or 
observations from cohort studies, the optimal information size provides reliable estimates on 
the number needed to evaluate this intervention.45 When we applied the median event rates at 
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80% and a 5% alpha, we found that 19,690 individuals with a similar baseline risk would need 
to be enrolled. 
 
B.5. Discussion 
 
There have been considerable expectations that DOT could be an effective intervention to 
promote adherence both for the general population21 and for groups at high risk of poor 
adherence.46 We did not find any evidence to support DOT for general populations, while the 
effect for high-risk groups in the sensitivity analysis was found to be on the margin of 
significance. Ours is not the first study to question the effectiveness of a DOT approach to 
chronic disease care: a similar lack of effect has been reported for DOT-TB treatment (RR 
1.02, 95% CI 0.86 to 1.21).17 Possible explanations of the intervention's lack of success in both 
meta-analyses include attrition due to the intensive clinic visitation requirement of daily 
observation that not all patients can meet,47 resistance by patients to losing their autonomy48 
and a desire to take responsibility for their own treatment,49 a possible lack of actual delivery of 
DOT in the intervention arm, and/or that patients maintain excellent ART adherence 
regardless of the intervention indicating that self-administration is a successful approach to 
long-term care.13,50  
 
Strengths of this systematic review include explicit eligibility criteria, and conduct of a 
comprehensive search that identified a number of eligible articles not published or available via 
electronic databases. We contacted all authors to complete missing information, and in most 
cases this was provided. Independent reviewers assessed eligibility and agreement was high. 
Our a priori explanations of heterogeneity did not find differing effects across study 
populations, time, or study quality, reinforcing the validity of our study findings.  
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A limitation to any adherence assessment is the lack of a ‘gold standard’ for evaluating 
adherence.23 We used a pharmacodynamic outcome (viral load) as our major outcome as we do 
not expect a placebo effect to influence pharmacodynamics.  Objective outcomes such as 
viremia may be influenced by both adherence and drug resistance, an issue that was not 
consistently evaluated across studies. We included studies that used both consistent (every 
dose) and modified DOT (select dosing) for varying study periods. Our sensitivity analysis did 
not find evidence that either type or duration of intervention affected study outcomes, 
although we recognize that short interventions may have residual effects by educating patients 
experiencing problems with adherence. The fact that all secondary outcomes (self-reported 
adherence, immunological change, all cause mortality, resistance mutations, and AIDS-defining 
events) were non-significant supports the inference of no major effects of DOT on virological 
suppression.  
 
Authors did not respond to requests to provide outcomes that are not in the public domain. 
This displays a publication-bia  that we infer as absent from for-profit motivations, but 
influenced by authors desire to publish findings as a full-text article initially, which is 
understandable. The largest of these trials (n=65051) reported in a conference abstract that no 
difference was detected between DOT and SAT arms. This, together with the large numbers of 
patients required to show a measurable effect as determined by the optimal information size 
gives us confidence that this missing data would not importantly change our findings.  
 
Conducting randomized evaluations of DOT is challenging as inclusion requires that patients 
be poorly adherent in order to measure an effect. Because patients on HAART generally 
display excellent adherence52 and viremia can be suppressed at varying levels of adherence,53 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 35 
enrolling an adequate population size to detect a difference is a major challenge.54,55 Although 
we found similar event rates of virological suppression, possible explanations beyond 
adherence include polypharmacy, drug resistance, treatment failure, and unknown effects of the 
disease or drugs.42,56,58 Studies enrolling patients at a high-risk of having events require patients 
that would experience multiple adherence failures and are capable of demonstrating virological 
escape. These populations are difficult to identify in programmes due to patient heightened 
self-report of successful adherence59 and the previously mentioned alternative explanations for 
viremia. It is worth noting that the goal of adherence is to prevent viremia (and resistance), 
rather than using clinical failures to identify poor adherence;42 thus using viral suppression as a 
primary outcome is important from a clinical perspective, but challenging from a 
methodological perspective. 
 
The impact of DOT has been argued to be more than just observed doses for both TB60 and 
HIV,61 because DOT programmes may educate patients and encourage interaction with health 
systems and peer supporters, which may be broadly beneficial.62 However, the absence of a 
measurable benefit together with the burden of direct observation for both patients and health 
services calls into question the specific role of direct observation in promoting adherence, 
particularly for the general patient population. Efforts to sustain adherence remain important 
to optimize individual and global HIV treatment outcomes, and ongoing efforts are required to 
evaluate to adherence support interventions, particularly for groups at high-risk of poor 
adherence. Considerations of cost and feasibility of administration, and acceptability by 
patients, should be a central part of this future research agenda. 
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B.7.1. Table 1: Trial characteristics 
 
VL, Viral Load; SAT, Self-Administered Therapy; DOT, Directly Observed Therapy.  
*Implementation of this trial was reported in an earlier paper.43  
 
 
 
 
Study Study 
population 
Age 
(Mean) 
Gender 
% male 
n Intervention 
 
Control Duration 
of follow 
up 
Outcome 
     Type Duration    
Wohl, 200630 Clinic 
population, 
USA 
82% 
over 30 
years 
75% 166 Partial DOT 
(Once daily) 
6 months SAT 6 months VL<400 
Macalino, 
200729 
Drug users, 
USA 
42 70% 87 Full DOT 
(Once daily 
regimen) 
3 months SAT 3 months VL<50 
Pearson, 
200735 
Clinic 
population, 
Mozambique 
36 46.3% 350 Partial DOT 
(Once daily) 
6 weeks SAT 12 
months 
Adherence 
(30 day 
recall) 
Sarna, 200834 Clinic 
population, 
Kenya 
37 36.3% 234 Partial DOT 
(Once daily, 
twice 
weekly) 
6 months SAT 18 
months 
VL<400 
Taiwo, 
200836 
Clinic 
population, 
Nigeria 
33 44% 500 Partial DOT 
(Once daily) 
6 months SAT 6 months VL<200 
Maru, 200928 Drug users, 
USA 
44 68.8% 141 Partial DOT 
(Once daily) 
6 months SAT 12 
months 
VL <400 
Nachega, 
200937 
Clinic 
population, 
South Africa 
36 42.3% 272 Full DOT 
 
24 months SAT 24 
months 
VL<50 
Mildvan, 
200939 
Clinic 
population 
Multi-site 
(US &South 
Africa 
39 79% 243 Partial DOT 
(weekdays 
only) 
6 months SAT 12 
months 
VL<200 
Karim, 
200938 
Clinic 
population, 
South Africa 
--- --- 58 Partial DOT 
(weekdays 
only) 
--- --- --- --- 
Bangsberg, 
200931 
Homeless 
population, 
USA 
42 80% 82 Partial DOT 
(weekdays 
only) 
3 months SAT 12 
months 
VL<400 
Grodensky, 
200932 
Prisoners, 
USA 
38 79% 43 Full DOT 12 months  12 
months 
Adherence 
(% doses 
taken) 
Arnsten, 
200933 
Drug users, 
USA 
47 53% 77 Partial DOT 
(weekdays 
only) 
6 months SAT 6 months VL<400 
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B.7.2. Table 2. Primary and main secondary outcomes 
 
 
Study Viral 
suppression 
(RR, 95% CI) 
Adherence 
(RR, 95% CI) 
CD4  
(SMD, 95% CI) 
LTFU**§ 
(RR, 95%CI) 
Mortality 
(RR, 95%CI) 
Wohl, 200630 1.00 
(0.75-1.33) 
1.03* 
(0.91-1.21) 
7 
(-51.12-65.12) 
0.82 
(0.46-1.45) 
0.51 
(0.07-3.84) 
Macalino, 200729 1.63 
(1.02-2.68) 
--- 44 
(-36.28-124.28) 
0.81 
(0.28-2.35) 
--- 
Pearson, 200735 --- 1.06 
(0.96-1.16) 
0.4 
(-2.47-3.28) 
1.00 
(0.18-5.62) 
0.50 
(0.16-1.53) 
Sarna, 200834 0.90 
(0.72-1.12) 
1.02* 
(0.95-1.10) 
-14 
(-62.95-34.95) 
1.14 
(0.63-2.06) 
1.40 
(0.60-3.27) 
Taiwo, 200836 1.23 
(1.05-1.45) 
--- --- --- --- 
Maru, 200928 1.02 
(0.77-1.40) 
--- -48.3 
(-113.38-16.79) 
11.44 
(2.08-66.53) 
1.20 
(0.16-9.10) 
Nachega, 200937 0.89 
(0.71-1.12) 
0.97 
(0.81-1.15) 
18 
(-26.5-62.5) 
1.00  
(0.42-2.38) 
0.45 
(0.22-0.93) 
Mildvan, 200939 0.72 
(0.51-1.00) 
1.01 
(0.91-1.09) 
-15 
(-7.0 – 4.0) 
0.88 
(0.48-1.57) 
0.49 
(0.07-3.19) 
Karim, 200938 0.95 
(0.67-1.35) 
--- --- 1.13 
(0.51-2.49) 
--- 
Bangsberg, 200931 1.02 
(0.88-1.17) 
--- -9 
(-96-78) 
0.30 
(0.02-4.02) 
0.30 
(0.02-4.02) 
Grodensky, 
200932 
--- 0.99 
(0.79-1.21) 
--- --- --- 
Arnsten, 200933  1.60 
(0.91-1.20) 
--- --- --- --- 
* Only a subset of patients were followed up for self-reported adherence 
** Includes refusals 
§ Loss to follow-up report d for period of intervention only 
SMD, standardized mean difference 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 46 
 
 
 
B.7.3. Figure 1. Identification process for elligible studies 
 
Full text papers reviewed 
(n=83) 
Studies considered eligible for 
inclusion (n=26) 
10 abstract databases & 5 grey 
literature websites searched 
 
Papers screened by title and 
abstract (n=942) 
 
 
Studies included in analysis 
(n=12) 
Papers excluded 
(859) 
 
Studies not included (16) 
Study ongoing (n=1) 
Data not provided (n=2) 
Duplicate reports (n=10) 
Not an RCT (n=3) 
Papers excluded 
(62) 
Additional Articles identified 
(bibliographies) 
(n=5) 
Additional Articles identified 
(conference abstracts) 
(n=2) 
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B.7.4. Figure 2: Effect of Direct observation of HAART on virological suppression 
compared to self-administration 
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B.7.5. Figure 3: Subgroup analysis for the effect of DOT viral suppression 
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PART C: ANNEXES
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Annex C.1. Investigator contributions 
 
 
Nathan Ford: was overall responsible for co-ordination of this study, from conception to 
submission. He conceived the study question; wrote the protocol; ran all searches; selected all 
studies; did the data extraction; assessed methodological quality; undertook all communications 
with investigators of published and unpublished studies; calculated all summary statistics; ran all 
meta-analyses; and wrote the first draft of the paper  
 
Jean Nachega: provided guidance on technical issues of adherence measurement; undertook 
additional searches, provided unpublished data for one of the included studies; and contributed to 
the writing of the paper. 
 
Mark Engel: provided supervision for the protocol design; arbitration for study inclusion and 
assessment of methodological quality; clarification of ambiguities in data extraction; contributed to 
the writing of the article; and managed the overall dissertation submission process. 
 
Ed Mills:  Provided technical guidance on methodological support and adherence measurement 
issues; acted as a duplicate for study selection, data extraction, and assessment of methodological 
quality; supervised the data analysis; and contributed to the writing of the paper. 
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ANNEX C2: META-ANALYSES 
C.2.1: Sensitivity Analyses of primary outcomes 
 
C.2.1.1. Hi gh r i sk g roups  vs  general populat ion 
 
Summary meta-analysis   
 
Stratum Relative Risk SE Approximate 95% CI % Weight (fixed, 
random) 
1 1.31 0.136863 1 1.71 26.322135 43.770134 High risk 
groups 
2 0.96 0.081805 0.82 1.13 73.677865 56.229866 General 
population 
 
Fixed effects (inverse variance) 
Pooled relative risk = 1.041852 (95% CI = 0.907897 to 1.195572) 
Z (test test relative risk differs from 1) = 0.5839  P = 0.5593 
 
Non-combinability of studies 
Cochran Q = 3.800702  (df = 1)  P = 0.0512 
Moment-based estimate of between studies variance = 0.035602 
I² (inconsistency) = *% (95% CI = *% to *%)  
 
Random effects (DerSimonian-Laird) 
Pooled relative risk = 1.09992 (95% CI = 0.813007 to 1.488085) 
Z (test test relative risk differs from 1) = 0.617567  P = 0.5369 
 
Bias indicators 
Begg-Mazumdar: Kendall's <too few strata>  * 
Egger: bias = <too few strata> (95% CI = * to *)  P = * 
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Summary meta-analysis plot [fixed effects]
0.5 1 2
combined 1.04 (0.91, 1.20)
General population 0.96 (0.82, 1.13)
High risk groups 1.31 (1.00, 1.71)
relative risk (95% confidence interval)
 
 
 
Summary meta-analysis plot [random effects]
0.5 1 2
combined 1.10 (0.81, 1.49)
General population 0.96 (0.82, 1.13)
High risk groups 1.31 (1.00, 1.71)
relative risk (95% confidence interval)
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C.2.1.2. Fu ll  vs  pa rt ia l  DOT 
 
Stratum Relative Risk SE Approximate 95% CI % Weight (fixed, random) 
1 1.16 0.296728 0.65 2.08 5.764581 5.764581 Full DOT 
2 1 0.07339 0.87 1.16 94.235419 94.235419 Partial 
DOT 
 
Fixed effects (inverse variance) 
Pooled relative risk = 1.008592 (95% CI = 0.87715 to 1.159733) 
Z (test test relative risk differs from 1) = 0.120093  P = 0.9044 
 
Non-combinability of studies 
Cochran Q = 0.235767  (df = 1)  P = 0.6273 
Moment-based estimate of between studies variance = 0 
I² (inconsistency) = *% (95% CI = *% to *%)  
 
Random effects (DerSimonian-Laird) 
Pooled relative risk = 1.008592 (95% CI = 0.87715 to 1.159733) 
Z (test test relative risk differs from 1) = 0.120093  P = 0.9044 
 
Bias indicators 
Begg-Mazumdar: Kendall's <too few strata>  * 
Egger: bias = <too few strata> (95% CI = * to *)  P = * 
 
 
Summary meta-analysis plot [fixed effects]
0.5 1 2 5
combined 1.01 (0.88, 1.16)
Partial DOT 1.00 (0.87, 1.16)
Full DOT 1.16 (0.65, 2.08)
relative risk (95% confidence interval)
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Summary meta-analysis plot [random effects]
0.5 1 2 5
combined 1.01 (0.88, 1.16)
Partial DOT 1.00 (0.87, 1.16)
Full DOT 1.16 (0.65, 2.08)
relative risk (95% confidence interval)
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 55 
C.2.1.3. Afri ca vs  USA 
 
 
Stratum Relative Risk SE Approximate 95% CI % Weight (fixed, random) 
1 1 0.09099 0.84 1.2 65.469232 65.469232 Africa 
2 1.05 0.125288 0.82 1.34 34.530768 34.530768 USA 
 
Fixed effects (inverse variance) 
Pooled relative risk = 1.01699 (95% CI = 0.880337 to 1.174856) 
Z (test test relative risk differs from 1) = 0.228837  P = 0.819 
 
Non-combinability of studies 
Cochran Q = 0.099285  (df = 1)  P = 0.7527 
Moment-based estimate of between studies variance = 0 
I² (inconsistency) = *% (95% CI = *% to *%)  
 
Random effects (DerSimonian-Laird) 
Pooled relative risk = 1.01699 (95% CI = 0.880337 to 1.174856) 
Z (test test relative risk differs from 1) = 0.228837  P = 0.819 
 
Bias indicators 
Begg-Mazumdar: Kendall's <too few strata>  * 
Egger: bias = <too few strata> (95% CI = * to *)  P = * 
 
 
Summary meta-analysis plot [fixed effects]
0.5 1 2
combined 1.02 (0.88, 1.17)
USA 1.05 (0.82, 1.34)
Africa 1.00 (0.84, 1.20)
relative risk (95% confidence interval)
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Summary meta-analysis plot [random effects]
0.5 1 2
combined 1.02 (0.88, 1.17)
USA 1.05 (0.82, 1.34)
Africa 1.00 (0.84, 1.20)
relative risk (95% confidence interval)
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C.2.1.4. Tria l du rat io n 
 
Stratum Relative Risk SE Approximate 95% CI % Weight (fixed, random) 
1 1.2 0.103437 0.98 1.47 27.976149 45.724744 <6M 
2 0.91 0.064466 0.8 1.03 72.023851 54.275256 >6M 
 
Fixed effects (inverse variance) 
Pooled relative risk = 0.983223 (95% CI = 0.883247 to 1.094514) 
Z (test test relative risk differs from 1) = -0.309258  P = 0.7571 
 
Non-combinability of studies 
Cochran Q = 5.151469  (df = 1)  P = 0.0232 
Moment-based estimate of between studies variance = 0.030835 
I² (inconsistency) = *% (95% CI = *% to *%)  
 
Random effects (DerSimonian-Laird) 
Pooled relative risk = 1.032702 (95% CI = 0.788263 to 1.352941) 
Z (test test relative risk differs from 1) = 0.233501  P = 0.8154 
 
Bias indicators 
Begg-Mazumdar: Kendall's <too few strata>  * 
Egger: bias = <too few strata> (95% CI = * to *)  P = * 
 
 
Summary meta-analysis plot [fixed effects]
0.5 1 2
combined 0.98 (0.88, 1.09)
>6M 0.91 (0.80, 1.03)
<6M 1.20 (0.98, 1.47)
relative risk (95% confidence interval)
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Summary meta-analysis plot [random effects]
0.5 1 2
combined 1.03 (0.79, 1.35)
>6M 0.91 (0.80, 1.03)
<6M 1.20 (0.98, 1.47)
relative risk (95% confidence interval)
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C.2.1.5. Al lo cat ion co ncea lment   
   
Stratum Relative Risk SE Approximate 95% CI % Weight (fixed, random) 
1 1.01 0.13421 0.78 1.32 25.791906 25.791906 Allocation 
concealment 
2 0.9 0.079123 0.77 1.05 74.208094 74.208094 Not 
allocation concealment 
 
Fixed effects (inverse variance) 
Pooled relative risk = 0.927169 (95% CI = 0.811225 to 1.059684) 
Z (test test relative risk differs from 1) = -1.109452  P = 0.2672 
 
Non-combinability of studies 
Cochran Q = 0.547801  (df = 1)  P = 0.4592 
Moment-based estimate of between studies variance = 0 
I² (inconsistency) = *% (95% CI = *% to *%)  
 
Random effects (DerSimonian-Laird) 
Pooled relative risk = 0.927169 (95% CI = 0.811225 to 1.059684) 
Z (test test relative risk differs from 1) = -1.109452  P = 0.2672 
 
Bias indicators 
Begg-Mazumdar: Kendall's <too few strata>  * 
Egger: bias = <too few strata> (95% CI = * to *)  P = * 
 
 
Summary meta-analysis plot [fixed effects]
0.5 1 2
combined 0.93 (0.81, 1.06)
Not allocation concealment 0.90 (0.77, 1.05)
Allocation concealment 1.01 (0.78, 1.32)
relative risk (95% confidence interval)
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Summary meta-analysis plot [random effects]
0.5 1 2
combined 0.93 (0.81, 1.06)
Not allocation concealment 0.90 (0.77, 1.05)
Allocation concealment 1.01 (0.78, 1.32)
relative risk (95% confidence interval)
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C.2.2. Secondary outcomes 
 
C.2.2.1. Adhe rence  
 
 
Stratum Table (xt, xc, nt, nc) 
1 35 32 1 2 Wohl, 2006 
2 151 143 24 32 Pearson, 2007 
3 75 85 2 4 Sarna, 2008 
4 88 91 49 46 Nachega, 2009 
5 74 137 6 12 Mildvan, 2009 
 
Stratum Relative risk 95% CI (Koopman) % Weights (fixed, random) 
1 1.032986 0.905066 1.206077 7.455269 13.900453 Wohl, 2006 
2 1.055944 0.962755 1.162107 32.390298 16.728491 Pearson, 2007 
3 1.019862 0.948111 1.098316 17.861193 41.807353 Sarna, 2008 
4 0.967033 0.811639 1.150729 20.612008 4.718069 Nachega, 2009 
5 1.006022 0.913485 1.085584 21.681233 22.845634 Mildvan, 2009 
 
Fixed effects (Mantel-Haenszel, Rothman-Boice) 
Pooled relative risk = 1.018638 (95% CI = 0.968332 to 1.071556) 
Chi² (test relative risk differs from 1) = 0.510696  (df = 1)  P = 0.4748 
 
Non-combinability of studies 
Cochran Q = 1.113129  (df = 4)  P = 0.8922 
Moment-based estimate of between studies variance = 0 
I² (inconsistency) = 0% (95% CI = 0% to 64.1%)  
 
Random effects (DerSimonian-Laird) 
Pooled relative risk = 1.021866 (95% CI = 0.984267 to 1.060901) 
Chi² (test relative risk differs from 1) = 1.278841  (df = 1)  P = 0.2581 
 
Bias indicators 
Begg-Mazumdar: Kendall's tau = -0.2  P = 0.4833 (low power) 
Egger: bias = -0.348093 (95% CI = -3.006497 to 2.310311)  P = 0.7049 
Horbold-Egger: bias = -0.387811 (92.5% CI = -2.671766 to 1.896143)  P = 0.6799 
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Bias assessment plot
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Relative risk meta-analysis plot (fixed effects)
0.5 1 2
Mildvan, 2009 1.01 (0.91, 1.09)
Nachega, 2009 0.97 (0.81, 1.15)
Sarna, 2008 1.02 (0.95, 1.10)
Pearson, 2007 1.06 (0.96, 1.16)
Wohl, 2006 1.03 (0.91, 1.21)
combined [fixed] 1.02 (0.97, 1.07)
relative risk (95% confidence interval)
 
 
 
Relative risk meta-analysis plot (random effects)
0.5 1 2
Mildvan, 2009 1.01 (0.91, 1.09)
Nachega, 2009 0.97 (0.81, 1.15)
Sarna, 2008 1.02 (0.95, 1.10)
Pearson, 2007 1.06 (0.96, 1.16)
Wohl, 2006 1.03 (0.91, 1.21)
combined [random] 1.02 (0.98, 1.06)
relative risk (95% confidence interval)
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C.2 .2.2 . Lo ss to  fo l low-up    
 
Stratum Table (xt, xc, nt, nc) 
1 16 20 66 64 Wohl, 2006 
2 5 6 39 37 Macalino, 2007 
3 2 2 173 173 Pearson, 2007 
4 19 17 97 101 Sarna, 2008 
5 19 1 69 52 Maru, 2009 
6 9 9 128 128 Nachega, 2009 
7 13 29 69 132 Mildvan, 2009 
8 9 8 20 21 Karim, 2009 
9 0.5 1 50.5 30 Bangsberg, 2009 
 
Stratum Relative risk 95% CI (Koopman) % Weights (fixed, random) 
1 0.819512 0.459195 1.453775 23.593767 23.129046 Wohl, 2006 
2 0.814394 0.280876 2.347887 7.246799 6.375787 Macalino, 2007 
3 1 0.17794 5.619861 2.38815 2.068247 Pearson, 2007 
4 1.136917 0.628193 2.061067 20.125773 21.668225 Sarna, 2008 
5 11.443182 2.082753 66.526288 1.490476 1.999814 Maru, 2009 
6 1 0.420587 2.377632 10.746673 9.847674 Nachega, 2009 
7 0.880151 0.482961 1.567845 23.370451 21.985168 Mildvan, 2009 
8 1.125 0.513138 2.486054 9.552598 12.232511 Karim, 2009 
9 0.303922 0.022913 4.02099 1.485313 0.693527 Bangsberg, 2009 
 
Fixed effects (Mantel-Haenszel, Rothman-Boice) 
Pooled relative risk = 1.100767 (95% CI = 0.835983 to 1.449417) 
Chi² (test relative risk differs from 1) = 0.467683  (df = 1)  P = 0.4941 
 
Non-combinability of studies 
Cochran Q = 7.797291  (df = 8)  P = 0.4535 
Moment-based estimate of between studies variance = 0 
I² (inconsistency) = 0% (95% CI = 0% to 54.4%)  
 
Random effects (DerSimonian-Laird) 
Pooled relative risk = 0.995512 (95% CI = 0.7522 to 1.317527) 
Chi² (test relative risk differs from 1) = 0.00099  (df = 1)  P = 0.9749 
 
Bias indicators 
Begg-Mazumdar: Kendall's tau = 0.111111  P = 0.7614 (low power) 
Egger: bias = 0.617897 (95% CI = -1.144248 to 2.380042)  P = 0.4344 
Horbold-Egger: bias = -0.052844 (92.5% CI = -2.377742 to 2.272053)  P = 0.9634 
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Bias assessment plot
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L'Abbe plot (symbol size represents sample size)
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Relative risk meta-analysis plot (fixed effects)
0.01 0.1 0.2 0.5 1 2 5 10 100
Bangsberg, 2009 0.30 (0.02, 4.02)
Karim, 2009 1.13 (0.51, 2.49)
Mildvan, 2009 0.88 (0.48, 1.57)
Nachega, 2009 1.00 (0.42, 2.38)
Maru, 2009 11.44 (2.08, 66.53)
Sarna, 2008 1.14 (0.63, 2.06)
Pearson, 2007 1.00 (0.18, 5.62)
Macalino, 2007 0.81 (0.28, 2.35)
Wohl, 2006 0.82 (0.46, 1.45)
combined [fixed] 1.10 (0.84, 1.45)
relative risk (95% confidence interval)
 
 
 
Relative risk meta-analysis plot (random effects)
0.01 0.1 0.2 0.5 1 2 5 10 100
Bangsberg, 2009 0.30 (0.02, 4.02)
Karim, 2009 1.13 (0.51, 2.49)
Mildvan, 2009 0.88 (0.48, 1.57)
Nachega, 2009 1.00 (0.42, 2.38)
Maru, 2009 11.44 (2.08, 66.53)
Sarna, 2008 1.14 (0.63, 2.06)
Pearson, 2007 1.00 (0.18, 5.62)
Macalino, 2007 0.81 (0.28, 2.35)
Wohl, 2006 0.82 (0.46, 1.45)
combined [random] 1.00 (0.75, 1.32)
relative risk (95% confidence interval)
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C.2 .2.3 . Morta li t y  
 
Stratum Table (xt, xc, nt, nc) 
1 1 2 81 82 Wohl, 2006 
2 4 8 171 167 Pearson, 2007 
3 11 8 105 110 Sarna, 2008 
4 2 1 86 52 Maru, 2009 
5 9 20 128 117 Nachega, 2009 
6 1 4 81 157 Mildvan, 2009 
7 0.5 1 50.5 30 Bangsberg, 2009 
 
Stratum Relative risk 95% CI (Koopman) % Weights (fixed, random) 
1 0.512195 0.067774 3.843903 4.584543 3.958879 Wohl, 2006 
2 0.5 0.162414 1.530627 18.56181 16.070871 Pearson, 2007 
3 1.398707 0.599988 3.274891 18.403162 29.388849 Sarna, 2008 
4 1.204545 0.161776 9.100943 2.896169 3.975395 Maru, 2009 
5 0.45 0.215055 0.932137 46.404525 39.87992 Nachega, 2009 
6 0.490854 0.07422 3.187219 6.263656 4.744186 Mildvan, 2009 
7 0.303922 0.022913 4.02099 2.886135 1.981901 Bangsberg, 2009 
 
Fixed effects (Mantel-Haenszel, Rothman-Boice) 
Pooled relative risk = 0.65692 (95% CI = 0.415006 to 1.039851) 
Chi² (test relative risk differs from 1) = 3.215559  (df = 1)  P = 0.0729 
 
Non-combinability of studies 
Cochran Q = 4.617085  (df = 6)  P = 0.5938 
Moment-based estimate of between studies variance = 0 
I² (inconsistency) = 0% (95% CI = 0% to 58.5%)  
 
Random effects (DerSimonian-Laird) 
Pooled relative risk = 0.665193 (95% CI = 0.414185 to 1.068319) 
Chi² (test relative risk differs from 1) = 2.844497  (df = 1)  P = 0.0917 
 
Bias indicators 
Begg-Mazumdar: Kendall's tau = 0.142857  P = 0.7726 (low power) 
Egger: bias = -0.180956 (95% CI = -2.144382 to 1.782469)  P = 0.8221 
Horbold-Egger: bias = -0.085707 (92.5% CI = -1.815148 to 1.643733)  P = 0.9158 
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Bias assessment plot
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Relative risk meta-analysis plot (fixed effects)
0.01 0.1 0.2 0.5 1 2 5 10
Bangsberg, 2009 0.30 (0.02, 4.02)
Mildvan, 2009 0.49 (0.07, 3.19)
Nachega, 2009 0.45 (0.22, 0.93)
Maru, 2009 1.20 (0.16, 9.10)
Sarna, 2008 1.40 (0.60, 3.27)
Pearson, 2007 0.50 (0.16, 1.53)
Wohl, 2006 0.51 (0.07, 3.84)
combined [fixed] 0.66 (0.42, 1.04)
relative risk (95% confidence interval)
 
 
 
Relative risk meta-analysis plot (random effects)
0.01 0.1 0.2 0.5 1 2 5 10
Bangsberg, 2009 0.30 (0.02, 4.02)
Mildvan, 2009 0.49 (0.07, 3.19)
Nachega, 2009 0.45 (0.22, 0.93)
Maru, 2009 1.20 (0.16, 9.10)
Sarna, 2008 1.40 (0.60, 3.27)
Pearson, 2007 0.50 (0.16, 1.53)
Wohl, 2006 0.51 (0.07, 3.84)
combined [random] 0.67 (0.41, 1.07)
relative risk (95% confidence interval)
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C.2 .2.4 . Dev el opment  o f n ew r e si stanc e mutat ions 
 
Stratum Table (xt, xc, nt, nc) 
1 5 0.5 65 44.5 Maru, 2009 
2 8 10 14 25 Mildvan, 2009 
 
Stratum Relative risk 95% CI (Koopman) % Weights (fixed, random) 
1 6.428571 0.65214 66.121629 7.309031 16.575341 Maru, 2009 
2 1.272727 0.58933 2.660259 92.690969 83.424659 Mildvan, 2009 
 
Fixed effects (Mantel-Haenszel, Rothman-Boice) 
Pooled relative risk = 1.64957 (95% CI = 0.781822 to 3.480435) 
Chi² (test relative risk differs from 1) = 1.726248  (df = 1)  P = 0.1889 
 
Non-combinability of studies 
Cochran Q = 1.300744  (df = 1)  P = 0.2541 
Moment-based estimate of between studies variance = 0.348031 
I² (inconsistency) = *% (95% CI = *% to *%)  
 
Random effects (DerSimonian-Laird) 
Pooled relative risk = 1.66465 (95% CI = 0.470025 to 5.895559) 
Chi² (test relative risk differs from 1) = 0.623856  (df = 1)  P = 0.4296 
 
Bias indicators 
Begg-Mazumdar: Kendall's <too few strata>  * 
Egger: bias = <too few strata> (95% CI = * to *)  P = * 
Horbold-Egger: bias = 2.244005 (92.5% CI = * to *)  P = * 
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Relative risk meta-analysis plot (fixed effects)
0.5 1 2 5 10 100
Mildvan, 2009 1.27 (0.59, 2.66)
Maru, 2009 6.43 (0.65, 66.12)
combined [fixed] 1.65 (0.78, 3.48)
relative risk (95% confidence interval)
 
 
 
Relative risk meta-analysis plot (random effects)
0.5 1 2 5 10 100
Mildvan, 2009 1.27 (0.59, 2.66)
Maru, 2009 6.43 (0.65, 66.12)
combined [random] 1.66 (0.47, 5.90)
relative risk (95% confidence interval)
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C.2.2.5. New or re cu rre nt  AIDS de f i nin g i l lne s s e s  
 
 
Stratum Table (xt, xc, nt, nc) 
1 12 8 70 76 Wohl, 2006 
2 23 25 114 112 Nachega, 2009 
3 1 11 81 150 Mildvan, 2009 
 
Stratum Relative risk 95% CI (Koopman) % Weights (fixed, random) 
1 1.536585 0.680283 3.498777 19.598581 36.78494 Wohl, 2006 
2 0.92 0.552353 1.530403 61.992463 51.853827 Nachega, 2009 
3 0.178492 0.029799 1.03656 18.408955 11.361233 Mildvan, 2009 
 
Fixed effects (Mantel-Haenszel, Rothman-Boice) 
Pooled relative risk = 0.904338 (95% CI = 0.593631 to 1.377669) 
Chi² (test relative risk differs from 1) = 0.219193  (df = 1)  P = 0.6397 
 
Non-combinability of studies 
Cochran Q = 3.984659  (df = 2)  P = 0.1364 
Moment-based estimate of between studies variance = 0.212712 
I² (inconsistency) = 49.8% (95% CI = 0% to 84.5%)  
 
Random effects (DerSimonian-Laird) 
Pooled relative risk = 0.922194 (95% CI = 0.436074 to 1.950221) 
Chi² (test relative risk differs from 1) = 0.044933  (df = 1)  P = 0.8321 
 
Bias indicators 
Begg-Mazumdar: Kendall's <too few strata>  * 
Egger: bias = <too few strata> (95% CI = * to *)  P = * 
Horbold-Egger: bias = -1.720099 (92.5% CI = -30.949199 to 27.509001)  P = 0.7063 
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Relative risk meta-analysis plot (fixed effects)
0.01 0.1 0.2 0.5 1 2 5
Mildvan, 2009 0.18 (0.03, 1.04)
Nachega, 2009 0.92 (0.55, 1.53)
Wohl, 2006 1.54 (0.68, 3.50)
combined [fixed] 0.90 (0.59, 1.38)
relative risk (95% confidence interval)
 
 
 
Relative risk meta-analysis plot (random effects)
0.01 0.1 0.2 0.5 1 2 5
Mildvan, 2009 0.18 (0.03, 1.04)
Nachega, 2009 0.92 (0.55, 1.53)
Wohl, 2006 1.54 (0.68, 3.50)
combined [random] 0.92 (0.44, 1.95)
relative risk (95% confidence interval)
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 Annex C.3. Overview of main search results 
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C.3.1. MEDLINE (via PUBMED) 
  
 
#36 Search #9 AND #19 AND #27 AND #35 66 
#35 Search #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 983948 
#34 Search meta-analy* [tw] 37210 
#33 Search meta analysis 34485 
#32 Search clinical trial 706135 
#31 Search single blind procedure 19734 
#30 Search double blind procedure 104920 
#29 Search random* [tw] 596934 
#28 Search randomization 73231 
#27 Search #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 99317 
#26 Search supervis* [tw] 32942 
#25 Search DAART 18 
#24 Search DOT 16579 
#23 Search directly observ* [tw] 2564 
#22 Search direct observ* [tw] 4974 
#21 Search directly observed 38925 
#20 Search direct observation 11112 
#19 Search #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 178640 
#18 Search nonadher* [tw] 4375 
#17 Search non-adher* [tw] 2685 
#16 Search adher* [tw] 90850 
#15 Search non-complian* [tw] 2870 
#14 Search noncomplian* [tw] 4767 
#13 Search complied [tw] 1990 
#12 Search comply [tw] 4899 
#11 Search complian* [tw] 89669 
#10 Search patient compliance 48171 
#9 Search #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 276693 
#8 Search aids [tw] 128030 
#7 Search acquired immune deficiency syndrome [tw] 4428 
#6 Search acquired immunodeficiency syndrome [tw] 76847 
#5 Search human immunodeficiency [tw] 59636 
#4 Search hiv [tw] 195015 
#3 Search anti human immunodeficiency virus agent 1340 
#2 Search human immunodeficiency virus infection 192209 
#1 Search human immunodeficiency virus 238917 
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C.3.2. EMBASE 
 
36 #9 AND #19 AND #27 AND #35 118 
35 #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 1,103,810 
34 meta AND analy* 58,997 
33 meta AND ('analysis'/exp OR 'analysis') 57,504 
32 clinical AND trial 786,410 
31 single AND ('blind'/exp OR 'blind') AND procedure 19,948 
30 double AND ('blind'/exp OR 'blind') AND procedure 92,662 
29 random* 574,002 
28 'randomization'/exp OR 'randomization' 56,240 
27 #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 166,068 
26 supervis* 34,275 
25 daart 20 
24 dot 19,082 
23 directly AND observ* 46,778 
22 direct AND observ* 72,958 
21 directly AND observed 35,623 
20 direct AND ('observation'/exp OR 'observation') 11,444 
19 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 213,496 
18 nonadher* 4,110 
17 non AND adher* 10,502 
16 adher* 94,357 
15 non AND complian* 14,658 
14 noncomplian* 5,356 
13 complied 2,251 
12 comply 5,917 
11 complian* 120,829 
10 ('patient'/exp OR 'patient') AND ('compliance'/exp OR 
'compliance') 
74,103 
9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 378,476 
8 'aids'/exp OR 'aids' 179,822 
7 acquired AND immune AND deficiency AND ('syndrome'/exp OR 
'syndrome') 
105,343 
6 acquired AND ('immunodeficiency'/exp OR 'immunodeficiency') 
AND ('syndrome'/exp OR 'syndrome') 
108,140 
5 ('human'/exp OR 'human') AND ('immunodeficiency'/exp OR 
'immunodeficiency') 
331,394 
4 'hiv'/exp OR 'hiv' 202,755 
3 anti AND ('human'/exp OR 'human') AND ('immunodeficiency'/exp 
OR 'immunodeficiency') AND ('virus'/exp OR 'virus') AND agent 
14,715 
2 ('human'/exp OR 'human') AND ('immunodeficiency'/exp OR 
'immunodeficiency') AND ('virus'/exp OR 'virus') AND 
('infection'/exp OR 'infection') 
203,879 
1 ('human'/exp OR 'human') AND ('immunodeficiency'/exp OR 
'immunodeficiency') AND ('virus'/exp OR 'virus') 
236,548 
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C.2.3. CINAHL 
 
 
# Query Limiters/Expanders Results 
S36 S9 and S19 and S27 and S35 Search modes - Boolean/Phrase 137 
S35 S28 or S29 or S30 or S31 or S32 or S33 or S34 Search modes - Boolean/Phrase 110445 
S34 TX meta-analy* Search modes - Boolean/Phrase 11765 
S33 meta AND analysis Search modes - Boolean/Phrase 10819 
S32 clinical AND trial Search modes - Boolean/Phrase 27809 
S31 single AND blind AND procedure Search modes - Boolean/Phrase 149 
S30 double AND blind AND procedure Search modes - Boolean/Phrase 286 
S29 TX random* Search modes - Boolean/Phrase 95607 
S28 randomization Search modes - Boolean/Phrase 1494 
S27 S20 or S21 or S22 or S23 or S24 or S25 or S26 Search modes - Boolean/Phrase 20346 
S26 TX supervis* Search modes - Boolean/Phrase 16718 
S25 DAART Search modes - Boolean/Phrase 6 
S24 DOT Search modes - Boolean/Phrase 481 
S23 TX directly AND observ* Search modes - Boolean/Phrase 2569 
S22 TX direct observ* Search modes - Boolean/Phrase 706 
S21 directly AND observed Search modes - Boolean/Phrase 1381 
S20 direct AND observation Search modes - Boolean/Phrase 932 
S19 S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 Search modes - Boolean/Phrase 36870 
S18 TX nonadher* Search modes - Boolean/Phrase 700 
S17 TX non-adher* Search modes - Boolean/Phrase 437 
S16 TX adher* Search modes - Boolean/Phrase 11406 
S15 TX non-complian* Search modes - Boolean/Phrase 626 
S14 TX noncomplian* Search modes - Boolean/Phrase 1314 
S13 TX complied Search modes - Boolean/Phrase 402 
S12 TX comply Search modes - Boolean/Phrase 1939 
S11 TX complian* Search modes - Boolean/Phrase 28440 
S10 patient compliance Search modes - Boolean/Phrase 11054 
S9 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 Search modes - Boolean/Phrase 60645 
S8 TX aids 
Expanders - Also search within the full text 
of the articles  
Search modes - Boolean/Phrase 
41161 
S7 TX acquired and immune and deficiency and syndrome 
Expanders - Also search within the full text 
of the articles  
Search modes - Boolean/Phrase 
538 
S6 TX acquired and immunodeficiency and syndrome 
Expanders - Also search within the full text 
of the articles  
Search modes - Boolean/Phrase 
11055 
S5 TX human and immunodeficiency 
Expanders - Also search within the full text 
of the articles  
Search modes - Boolean/Phrase 
6716 
S4 TX hiv 
Expanders - Also search within the full text 
of the articles  
Search modes - Boolean/Phrase 
41531 
S3 anti and human and immunodeficiency and virus and agent Search modes - Boolean/Phrase 6 
S2 human and immunodeficiency and virus and infection Search modes - Boolean/Phrase 2498 
S1 human and immunodeficiency and virus Search modes - Boolean/Phrase 5872 
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C.5.4. COCHRANE 
 
Search History 
ID Search Hits 
#1 (human immunodeficiency virus) 2662 
#2 human immunodeficiency virus infection 2224 
#3 anti human immunodeficiency virus agent 605 
#4 (hiv) 7297 
#5 (human immunodeficiency virus infection) 2224 
#6 (acquired immunodeficiency syndrome) 1591 
#7 (acquired immune deficiency syndrome) 862 
#8 (aids) 9520 
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8) 13610 
#10 (patient compliance) 13224 
#11 (complian*) 15704 
#12 (comply) 1015 
#13 (complied) 1015 
#14 (noncomplian*) 655 
#15 (non-complian*) 750 
#16 (adher*) 5553 
#17 (non-adher*) 214 
#18 (nonadher*) 219 
#19 (#10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18) 20205 
#20 (direct observation) 1591 
#21 (directly observed) 1993 
#22 (direct observ*) 5949 
#23 (directly observ*) 2717 
#24 (DOT ) 833 
#25 (DAART) 12 
#26 (supervis*) 3126 
#27 (#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26) 10954 
#28 (randomization) 17470 
#29 (random*) 349074 
#30 (double blind procedure) 16964 
#31 (single blind procedure) 6242 
#32 (clinical trial) 392464 
#33 (meta analysis ) 134293 
#34 (meta-analy*) 13382 
#35 (#28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34) 479627 
#36 (#9 AND #19 AND #27 AND #35) 389 
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C.4.4 PsychInfo 
 
Searches Results Search  
1 
(human and immunodeficiency and virus).mp. [mp=title, abstract, heading word, 
table of contents, key concepts] 
3310 
2 
(human and immunodeficiency and virus and infection).mp. [mp=title, abstract, 
heading word, table of contents, key concepts] 
1527 
3 
(anti and human and immunodeficiency and virus and agent).mp. [mp=title, 
abstract, heading word, table of contents, key concepts] 
3 
4 hiv.mp. [mp=title, abstract, heading word, table of contents, key concepts] 22265 
5 
(human and immunodeficiency).mp. [mp=title, abstract, heading word, table of 
contents, key concepts] 
3355 
6 
(acquired and immunodeficiency and syndrome).mp. [mp=title, abstract, heading 
word, table of contents, key concepts] 
1561 
7 
(acquired and immune and deficiency and syndrome).mp. [mp=title, abstract, 
heading word, table of contents, key concepts] 
2859 
8 aids.mp. [mp=title, abstract, heading word, table of contents, key concepts] 25580 
9 6 or 3 or 7 or 2 or 8 or 1 or 4 or 5 34941 
10 
(patient and compliance).mp. [mp=title, abstract, heading word, table of 
contents, key concepts] 
3629 
11 
complian*.mp. [mp=title, abstract, heading word, table of contents, key 
concepts] 
18380 
12 comply.mp. [mp=title, abstract, heading word, table of contents, key concepts] 1654 
13 complied.mp. [mp=title, abstract, heading word, table of contents, key concepts] 490 
14 
noncomplian*.mp. [mp=title, abstract, heading word, table of contents, key 
concepts] 
2697 
15 
non-complian*.mp. [mp=title, abstract, heading word, table of contents, key 
concepts] 
600 
16 adher*.mp. [mp=title, abstract, heading word, table of contents, key concepts] 12011 
17 
non-adher*.mp. [mp=title, abstract, heading word, table of contents, key 
concepts] 
375 
18 
nonadher*.mp. [mp=title, abstract, heading word, table of contents, key 
concepts] 
688 
19 11 or 17 or 12 or 15 or 14 or 18 or 10 or 13 or 16 29687 
20 (direct and observation).mp. [mp=title, abstract, heading word, table of contents, 2983 
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key concepts] 
21 
(directly and observed).mp. [mp=title, abstract, heading word, table of contents, 
key concepts] 
2445 
22 
(direct and observ*).mp. [mp=title, abstract, heading word, table of contents, 
key concepts] 
8631 
23 
(directly and observ*).mp. [mp=title, abstract, heading word, table of contents, 
key concepts] 
4400 
24 DOT.mp. [mp=title, abstract, heading word, table of contents, key concepts] 2951 
25 DAART.mp. [mp=title, abstract, heading word, table of contents, key concepts] 7 
26 supervis*.mp. [mp=title, abstract, heading word, table of contents, key concepts] 30307 
27 25 or 22 or 21 or 24 or 26 or 23 or 20 45518 
28 
randomization.mp. [mp=title, abstract, heading word, table of contents, key 
concepts] 
1457 
29 random*.mp. [mp=title, abstract, heading word, table of contents, key concepts] 79328 
30 
(double and blind and procedure).mp. [mp=title, abstract, heading word, table of 
contents, key concepts] 
342 
31 
(single and blind and procedure).mp. [mp=title, abstract, heading word, table of 
contents, key concepts] 
61 
32 
(clinical and trial).mp. [mp=title, abstract, heading word, table of contents, key 
concepts] 
10082 
33 
(meta and analysis).mp. [mp=title, abstract, heading word, table of contents, key 
concepts] 
8895 
34 
meta-analy*.mp. [mp=title, abstract, heading word, table of contents, key 
concepts] 
9862 
35 33 or 32 or 34 or 28 or 30 or 31 or 29 93933 
36 35 and 27 and 19 and 9 9 
37 35 and 27 and 19 and 9 9 
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Title Trial number Status Include/exclude Reason Published Y/N 
DOT-HAART for HIV-Infected South 
African Adults 
NCT00076804 
 
Terminated 
(futility) 
Include CROI 2009 
#143 
Directly Observed Therapy (DOT) in 
HIV-1 Infected Adolescents 
NCT00259389 
 
Active Exclude 
Non-randomized 
 
Strategies for Delivering Anti-HIV 
Therapy in South Africa 
NCT00080522 Completed Include  
Directly Observed Therapy for 
Community-Released HIV+ Prisoners 
 
NCT00786396 
 
Recruiting Include  
Depression Treatment to Improve 
Antiretroviral Adherence 
 
NCT00338767 Recruiting Exclude 
DOT is for anti-depressants 
 
The Adult Antiretroviral Treatment and 
Resistance Study (Tshepo) 
 
NCT00197613 
 
Completed Include Bussmann: 
JAIDS 2009 
Effectiveness of Directly Observed 
Therapy in Combined HIV and 
Tuberculosis Treatment in Resource-
Limited Settings 
NCT00091936 Completed Include  
Directly Observed Therapy in High 
Risk Populations in Newark, NJ 
 
NCT00285883 
 
Completed Exclude 
Single arm trial 
 
A Study to Compare Anti-HIV Drugs 
Given Twice a Day or Once a Day, 
With or Without Direct Observation 
 
NCT00036452 Completed Include  
Directly Observed Antiretroviral 
Therapy Among Active Drug Users 
NCT00367172 Completed Include Altice: CID 
2007 
Modified Directly Observed Therapy 
for Improving Antiretroviral Therapy 
Adherence in People With HIV 
NCT00339092 
 
Recruiting Include  
Effectiveness of Enhanced Counseling 
and Observed Therapy on 
Antiretroviral Adherence in People 
With HIV 
NCT00602758 Ongoing but 
not 
recruiting 
Include  
 
 
 
 
